Longevity & Aging · Metabolic & Cardiometabolic
statin therapy increases type 2 diabetes risk to a degree greater than the small regulatory framing suggests
In plain terms: Do statins raise diabetes risk more than the small label suggests?
Partly supported and clinically important: statins clearly and reproducibly raise new-onset diabetes (about 9-12% relative, dose-dependent, higher in prediabetes), which is more than trivial for at-risk patients — but in most populations the CVD benefit still outweighs it.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
Causal-review pass (2026-08-14) — `causal_basis: rct`. The causal link here rests on randomised evidence, and it is the strongest tier available: Sattar 2010 (13 trials, 91,140 patients, OR 1.09), Preiss 2011 (intensive vs moderate dosing, OR 1.12 -- a dose-response within randomised comparisons), and Thakker 2016 (network meta-analysis of RCTs).
The evidence (7)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Masson W, Lobo M, Barbagelata L, Nogueira JP 2024 · Acta Diabetol | meta-analysis | mixed | moderate | Primary-prevention meta-analysis: diabetes risk concentrated in those with baseline diabetes risk factors (prediabetes/metabolic syndrome) — supports that magnitude is understated for at-risk subgroups while near-null for low-risk. |
| Thakker D, Nair S, Pagada A, Jamdade V, Malik A 2016 · Pharmacoepidemiol Drug Saf | meta-analysis | supports | moderate | Network meta-analysis of RCTs finds statins as a class raise new-onset diabetes risk, with heterogeneity by agent and dose. |
| Li W, Wang D, Lin C, Cai T, Zhao M, Liang L, Zhao X, He X, Liang X, Zheng J 2025 · Cardiovasc Drugs Ther | meta-analysis | tested-null | low | Pooled analysis of statin adverse reactions across diseases quantifies elevated incidence of new-onset diabetes among statin users. |
| Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK 2011 · JAMA | meta-analysis | supports | high | Intensive vs moderate statin dosing: additional 12% relative rise in new diabetes (OR 1.12), NNH about 498/year — establishes dose-dependence, strengthening more-than-a-footnote framing. |
| Singh H, Kaur S, Kaushal P, Sharma J, Singla M 2024 · Expert Rev Clin Pharmacol | meta-analysis | mixed | moderate | Pitavastatin carries lower NODM risk than atorvastatin/rosuvastatin — shows risk is agent- and potency-dependent, not a uniform small class effect. |
| Seo WW, Seo SI, Kim Y, Yoo JJ, Shin WG, Kim J, You SC, Park RW, Park YM, Kim KJ, Rhee SY, Park M, Jin ES, Kim SE 2022 · Cardiovasc Diabetol | observational | mixed | moderate | Distributed-network analysis of 10 real-world databases confirms statins raise new-onset diabetes, with atorvastatin/rosuvastatin higher than pitavastatin. |
| Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I 2010 · Lancet | meta-analysis | supports | high | 13 trials/91,140 patients: statins raised incident diabetes OR 1.09 (9% relative increase), about 1 extra case per 255 patient-years — real but modest; the foundational estimate. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.